JP2025506474A5 - - Google Patents

Info

Publication number
JP2025506474A5
JP2025506474A5 JP2024547308A JP2024547308A JP2025506474A5 JP 2025506474 A5 JP2025506474 A5 JP 2025506474A5 JP 2024547308 A JP2024547308 A JP 2024547308A JP 2024547308 A JP2024547308 A JP 2024547308A JP 2025506474 A5 JP2025506474 A5 JP 2025506474A5
Authority
JP
Japan
Prior art keywords
diabetes
disease
pharmaceutical composition
composition according
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024547308A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025506474A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2023/074938 external-priority patent/WO2023151575A1/en
Publication of JP2025506474A publication Critical patent/JP2025506474A/ja
Publication of JP2025506474A5 publication Critical patent/JP2025506474A5/ja
Pending legal-status Critical Current

Links

JP2024547308A 2022-02-09 2023-02-08 ヘテロ環glp-1アゴニスト Pending JP2025506474A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2022075603 2022-02-09
CNPCT/CN2022/075603 2022-02-09
PCT/CN2023/074938 WO2023151575A1 (en) 2022-02-09 2023-02-08 Heterocyclic glp-1 agonists

Publications (2)

Publication Number Publication Date
JP2025506474A JP2025506474A (ja) 2025-03-11
JP2025506474A5 true JP2025506474A5 (cg-RX-API-DMAC10.html) 2026-02-17

Family

ID=87563628

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024547308A Pending JP2025506474A (ja) 2022-02-09 2023-02-08 ヘテロ環glp-1アゴニスト

Country Status (5)

Country Link
US (1) US20250145596A1 (cg-RX-API-DMAC10.html)
EP (1) EP4476213A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025506474A (cg-RX-API-DMAC10.html)
CN (1) CN119072474A (cg-RX-API-DMAC10.html)
WO (1) WO2023151575A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021219019A1 (en) 2020-04-29 2021-11-04 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
PE20231181A1 (es) 2020-08-06 2023-08-11 Gasherbrum Bio Inc Agonistas del glp-1 heterociclicos
SI4408840T1 (sl) 2021-09-27 2025-12-31 Terns Pharmaceuticals, Inc. Benzimidazolne karboksilne kisline kot agonisti GLP-1R
US12024507B2 (en) 2021-10-25 2024-07-02 Terns Pharmaceuticals, Inc. Compounds as GLP-1R agonists
EP4476216A4 (en) * 2022-02-09 2025-12-03 Gasherbrum Bio Inc GLP-1 HETEROCYCLIC AGONISTS
AU2023224854A1 (en) 2022-02-23 2024-10-03 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
EP4777197A2 (en) 2023-09-14 2026-07-22 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025109387A1 (en) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2316827B1 (en) * 2003-07-30 2016-01-27 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents
WO2018109607A1 (en) * 2016-12-16 2018-06-21 Pfizer Inc. Glp-1 receptor agonists and uses thereof
CA3045644C (en) * 2018-06-13 2024-01-16 Pfizer Inc. Glp-1 receptor agonists and uses thereof
EA202191432A1 (ru) * 2018-11-22 2021-10-14 Цилу Регор Терапьютикс Инк. Агонисты glp-1r и их применения
CA3140972C (en) * 2019-05-20 2024-06-18 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
WO2021249492A1 (zh) * 2020-06-10 2021-12-16 南京明德新药研发有限公司 甲基取代的苯并二噁唑类化合物及其应用
TW202214610A (zh) * 2020-06-19 2022-04-16 大陸商江蘇恆瑞醫藥股份有限公司 6-側氧-3,6-二氫吡啶類衍生物、其製備方法及其在醫藥上的應用
WO2021259309A1 (zh) * 2020-06-24 2021-12-30 广州市恒诺康医药科技有限公司 Glp-1受体激动剂及其药物组合物和用途
PE20231181A1 (es) * 2020-08-06 2023-08-11 Gasherbrum Bio Inc Agonistas del glp-1 heterociclicos
EP4476216A4 (en) * 2022-02-09 2025-12-03 Gasherbrum Bio Inc GLP-1 HETEROCYCLIC AGONISTS

Similar Documents

Publication Publication Date Title
JP2025513071A5 (cg-RX-API-DMAC10.html)
JP2025506473A5 (cg-RX-API-DMAC10.html)
JP2023515404A5 (cg-RX-API-DMAC10.html)
JP2025504508A5 (cg-RX-API-DMAC10.html)
JP7358338B2 (ja) 高血糖症の治療で使用するためのヘテロアリール置換されたベータ-ヒドロキシエチルアミン
JP2023540609A5 (cg-RX-API-DMAC10.html)
JP2025510741A5 (cg-RX-API-DMAC10.html)
US12280023B2 (en) Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia
JP2023540558A5 (cg-RX-API-DMAC10.html)
US20240294525A1 (en) Compounds as glp-1 receptor agonists and uses thereof
JP2023537501A5 (cg-RX-API-DMAC10.html)
JP2021091683A5 (cg-RX-API-DMAC10.html)
TWI864650B (zh) Glp-1受體激動劑化合物之新穎鹽類、其製備方法以及包含其之醫藥組合物
TW200835482A (en) GPCR agonists
TW201038545A (en) Bridged and fused antidiabetic compounds
JP2023546125A5 (cg-RX-API-DMAC10.html)
CN121985948A (zh) Glp-1r激动剂的制剂及其制备方法
CA3133768A1 (en) Heterocyclyl(phenyl)methanol compounds useful in the treatment of hyperglycaemia
CN102803255A (zh) 新的gpr119激动剂
KR20240116482A (ko) 과혈당증 및 2형 당뇨병 치료를 위한 (r)-2-(tert-부틸아미노)-1-(5-플루오로피리딘-3-일)-에탄-1-올 헤미-타르트레이트 염의 결정질 형태
JP2022525948A (ja) 高血糖症の治療に有用なヘテロアリール(ヘテロシクリル)メタノール化合物
WO2016068453A1 (en) Compound having gpr119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component
US20100022554A1 (en) Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia
JP6782763B2 (ja) 新規のピリジニウム化合物
US10428055B2 (en) Substituted piperidines having GPR119 agonistic activity